CD274 and neoplasm: While PD-1 inhibitors act on PD-L1 and PD-L2 receptors of human T cells, the action site of PD-L1 depressors is only on PD-L1 of T cells and tumor cells, thus explaining why PD-L1 treatment has a lower toxicity with less collateral damage to the human body44.